Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Amgen's poker face

How Amgen leveraged FOCUS news to shave $400M off Onyx purchase price

SEC filings posted last week detailing the negotiations between Amgen Inc. and Onyx Pharmaceuticals Inc. show that Amgen managed to shave more than $400 million off the final price based on interim Phase III data for multiple myeloma drug Kyprolis carfilzomib.

The data from the FOCUS trial, which emerged in late July, also scared off the only other offer Onyx was still seriously entertaining.

What was known prior to the filing was that Amgen

Read the full 725 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers